Skip to content

Insider · CIK 0001591467

John P. Butler

ceopresidentofficerdirector

Files at AKBA (Akebia Therapeutics, Inc.). First filing Feb 4, 2025, latest Mar 4, 2025.

Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 2
$0 bought, $388k sold

Where the trades landed

Last year at the company this insider has traded most, with each buy and sell on the bar it happened.

AKBA: Akebia Therapeutics, Inc.

AKBAOct 9, 2026 · close 0.80

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™

Signals

This insider’s open-market buys and sells, scored.

ScoreCompanyValueHoldingsPrice contextFiled
22Weak
AKBAsell 210b5-1
Akebia Therapeutics, Inc.
$85k
46,409 shares
-2%-
34Weak
AKBAsell 410b5-1
Akebia Therapeutics, Inc.
$303k
144,250 shares
-5%-

Transactions

Every row this insider has filed, newest first.

DateCompanyTransactionSharesPriceValueHoldings afterFiled
Mar 3, 2025AKBA
Akebia Therapeutics, Inc.
SOpen-market sale
Common Stock10b5-1
-46,409$1.83$85k2,557,921Mar 4, 2025
Jan 31, 2025AKBA
Akebia Therapeutics, Inc.
AGrant or award
Common Stock10b5-1
+701,000$0.00$02,748,580Feb 4, 2025
Feb 3, 2025AKBA
Akebia Therapeutics, Inc.
SOpen-market sale
Common Stock10b5-1
-46,268$2.10$97k2,702,312Feb 4, 2025
Feb 3, 2025AKBA
Akebia Therapeutics, Inc.
SOpen-market sale
Common Stock10b5-1
-97,982$2.10$206k2,604,330Feb 4, 2025
Jan 31, 2025AKBA
Akebia Therapeutics, Inc.
AGrant or award
Performance Stock Unitsderivative10b5-1
+350,500$0.00$0350,500Feb 4, 2025
Jan 31, 2025AKBA
Akebia Therapeutics, Inc.
AGrant or award
Stock Option (Right to buy)derivative10b5-1
+1,051,400$0.00$01,051,400Feb 4, 2025

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

John P. Butler: insider trades and track record | InsiderTell